

1.1 Senator moves to amend S.F. No. 278, in conference committee, as follows:

1.2 On R4, Senate language, (S0278-4)

1.3 Page 3, delete subdivision 17 and insert:

1.4 "Subd. 17. **Speciality drug.** "Specialty drug" means a prescription drug that:

1.5 (1) cannot be routinely dispensed at a majority of retail pharmacies;

1.6 (2) is used to treat chronic and complex, or rare medical conditions;

1.7 (3) has special storage, handling, or distribution requirements that typically cannot be

1.8 met by a retail pharmacy; and

1.9 (4) meets at least three of the following criteria:

1.10 (i) requires complex and extended patient education and counseling;

1.11 (ii) requires intensive monitoring;

1.12 (iii) requires clinical oversight; and

1.13 (iv) requires product support services."

1.14 Page 4, delete subdivision 20 and insert:

1.15 "Subd. 20. **Specialty pharmacy.** "Specialty pharmacy" means a pharmacy that specializes

1.16 in dispensing specialty drugs for patients with serious health conditions requiring complex

1.17 therapies and high cost biotech and injectable medications. A pharmacy benefit manager

1.18 or health carrier may require a specialty pharmacy to be accredited as a specialty pharmacy

1.19 from one of the following accrediting organizations:

1.20 (1) Utilization Review Accreditation Commission (URAC);

1.21 (2) Accreditation Commissioner for Health Care, Inc.; or

1.22 (3) Joint Accreditation Commission."